Robert Brown, MD Columbia University Medical Center New York, NY
Jointly sponsored by The Annenberg Center for Health Sciences at Eisenhower and the Chronic Liver Disease Foundation.
This activity
supported by:
Janssen Therapeutics Vertex Pharmaceuticals
Target Audience
This activity was developed for gastroenterologists and hepatologists and other health care providers managing patients with HCV.
Statement of Need/Program
Overview
The purpose of this activity is to enhance the care of patients with Hepatitis C.
Educational Objectives
At the conclusion of this initiative, participants will do the following:
•
Describe development goals for future therapies for the treatment of chronic hepatitis C
•
Assess potential efficacy and safety of new orally effective compounds currently under investigation for the treatment of chronic hepatitis C
•
Recognize how new compounds might fit into the future treatment armamentarium for chronic hepatitis C
•
Assess safety profile of peginterferon lambda-1a compared to peginterferon alfa-2a in patients with HCV
•
Evaluate efficacy and safety of direct acting antiviral agents in combination with peginterferon and ribavirin in difficult-to-treat patients with chronic hepatitis C
•
Recognize continuing importance of peginterferon and ribavirin in combination with direct acting antiviral agents in the treatment of chronic hepatitis C
Physician Accreditation
Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Annenberg Center for Health Sciences at Eisenhower and the Chronic Liver Disease Foundation. The Annenberg Center is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is an enduring material and consists of a web activity. Successful completion is achieved by reading and viewing the material, reflecting on its implications in your practice, and completing the assessment component.
Cost of activity
There is no charge for this activity.
Faculty Disclosure Statement
It is the policy of the Annenberg Center to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty and planners participating in sponsored programs are expected to identify and reference off-label product use and disclose any relationship with those supporting the activity or any others with products or services available within the scope of the topic being discussed in the educational presentation.
The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME/CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.
In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center policy, the following disclosures have been made:
Robert Brown, MD Grants/Research Support: Hyperion, Salix Consultant/Speaker's Bureau: Salix
Stay Informed!
